The mainstay of therapy for papillary thyroid cancer (PTC) is surgical excision, consisting of total thyroidectomy. Lymph node recurrence following thyroidectomy is a substantial clinical problem. In an attempt to decrease recurrence, prophylactic central neck dissection is often performed along with total thyroidectomy. Based only on expert opinion, current American Thyroid Association (ATA) practice guidelines recommend prophylactic central neck dissection. However, addition of a prophylactic central neck dissection may not be necessary for the majority of patients and may substantially increase postsurgical morbidities of hypocalcemia and deficits in swallowing, communicative function and health-related quality of life (HR-QOL). The probability and extent of these morbidities are currently unknown. Before routine central neck dissection can be adopted as a standard treatment it is important that the true risks and benefits of this procedure are systematically examined. The fact that only expert opinion guides this recommendation argues for the need for a prospective clinical trial to fully evaluate this common and potentially morbid clinical problem. Our hypothesis is that total thyroidectomy with prophylactic central neck dissection results in an increased rate of complications in comparison with total thyroidectomy alone for PTC without an associated benefit to the patient. We will test this hypothesis with a randomized clinical trial in which 140 patients undergoing total thyroidectomy for PTC with no preoperative evidence of distant or cervical lymph node metastasis will be randomized into one of two groups: prophylactic central neck dissection or no central neck dissection. This work has four specific aims in which patients with PTC undergoing total thyroidectomy with central neck dissection will be contrasted with those undergoing total thyroidectomy alone: (1) To determine the rate of transient and persistent hypocalcemia; (2) To determine the rate of voice and swallowing problems; (3) To determine the degree to which HR-QOL is compromised; and, (4) To determine clinical recurrence rates. The results of the proposed research will lead to an increased understanding of the manner in which prophylactic central neck dissection affects critical functions of the head and neck and cancer recurrence in patients with PTC. Due to the potentially serious and pervasive problems encountered in communicative function and swallowing in patients with PTC, it is of great importance to add to this knowledge base, to test interventions, and to lay the groundwork for evidence-based practice, particularly for untested surgical interventions in current use. Our findings have a high likelihood of yielding meaningful findings and solid evidence related to an important clinical issue.

Public Health Relevance

Thyroid cancer is usually treated with the complete surgical removal of the thyroid gland, but due to concerns that the cancer may recur in the future, lymph nodes in the central part of the neck may also be surgically removed. Unfortunately, the additional lymph node surgery may be associated with increased risks for complications such as inadequate calcium, problems with voice function, swallowing deficits, and generally diminished quality of life. Because the risks for these complications are poorly defined, we propose to do a randomized clinical trial where we will compare clinical recurrence rates and complication levels in patients with papillary thyroid cancer who have thyroid gland removal alone to those who receive thyroid gland removal plus lymph node surgery in the central neck.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA176911-05
Application #
9399625
Study Section
Motor Function, Speech and Rehabilitation Study Section (MFSR)
Program Officer
O'Mara, Ann M
Project Start
2014-01-01
Project End
2019-12-31
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Surgery
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Kletzien, Heidi; Macdonald, Cameron L; Orne, Jason et al. (2018) Comparison Between Patient-Perceived Voice Changes and Quantitative Voice Measures in the First Postoperative Year After Thyroidectomy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 144:995-1003
Krekeler, Brittany N; Wendt, Elizabeth; Macdonald, Cameron et al. (2018) Patient-Reported Dysphagia After Thyroidectomy: A Qualitative Study. JAMA Otolaryngol Head Neck Surg 144:342-348
Bates, Maria F; Lamas, Marcos R; Randle, Reese W et al. (2018) Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 163:118-123
Price, Amanda K; Randle, Reese W; Schneider, David F et al. (2017) Papillary thyroid microcarcinoma: decision-making, extent of surgery, and outcomes. J Surg Res 218:237-245
Randle, Reese W; Bushman, Norah M; Orne, Jason et al. (2017) Papillary Thyroid Cancer: The Good and Bad of the ""Good Cancer"". Thyroid 27:902-907
Lou, Irene; Chennell, Todd B; Schaefer, Sarah C et al. (2017) Optimizing Outpatient Pain Management After Thyroid and Parathyroid Surgery: A Two-Institution Experience. Ann Surg Oncol 24:1951-1957
Brekke, Andrew; Elfenbein, Dawn M; Madkhali, Tariq et al. (2016) When patients call their surgeon's office: an opportunity to improve the quality of surgical care and prevent readmissions. Am J Surg 211:599-604
Balentine, Courtney J; Sippel, Rebecca S (2016) Outpatient Thyroidectomy: Is it Safe? Surg Oncol Clin N Am 25:61-75
Oltmann, Sarah C; Alhefdhi, Amal Y; Rajaei, Mohammad H et al. (2016) Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures. Ann Surg Oncol 23:2874-82
Yu, Xiao-Min; Jaskula-Sztul, Renata; Georgen, Maria R et al. (2016) Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression. Clin Cancer Res 22:3582-92

Showing the most recent 10 out of 20 publications